

Background

Tetrodotoxin (TTX) is a small molecule inhibitor of voltage-gated sodium channels. It is postulated that the compound causes analgesia via inhibition of initiation and conduction of action potentials in the peripheral nervous system. TTX is under investigation for the treatment of chemotherapy induced neuropathic pain (CINP) and cancer pain.

Study Design

randomized, double-blind, dose-finding, Phase placebo-controlled, multicenter study of the potential efficacy and safety of TTX in subjects with chemotherapy induced neuropathic pain (CINP).

Objectives

Primary: To identify up to 2 doses / regimens of TTX for phase III evaluation

Secondary: To determine the safety and tolerability of multiple doses / regimens of TTX

Key Inclusion Criteria

- Adults (\geq 18 years) with moderate to severe CINP attributed to a taxane or platinum chemotherapy
- Stable baseline pain intensity ≥ 4 (/10), for at least one week
- Thirty day washout from chemotherapy
- ECOG 0 or 1
- No evidence of progressive disease

Key Exclusion Criteria

- History of peripheral neuropathy due to causes other than chemotherapy, or receiving concurrent agents known to cause peripheral neuropathy
- Concurrent cancer treatment
- Use of other sodium channel blocking agents, alternative therapies, or investigational agents
- Significant respiratory disease, renal impairment, cardiac arrhythmia, or pregnancy

Tetrodotoxin for Chemotherapy Induced Neuropathic Pain Samuel Goldlust, M.D.,¹ Mehran Kavoosi, B.Sc.², Walter Korz, HCA², Kenneth Deck, M.D.³ ¹John Theurer Cancer Center, Hackensack, NJ; ²WEX Pharmaceuticals Inc., Vancouver, BC; ³Alliance Research Centers, Laguna Hills, CA

Dosing Cohorts

Patients with taxane or platinum induced CINP were randomized to one of five cohorts. TTX or placebo was injected subcutaneously for four consecutive days.

Cohort	ohort n	Drug Dose (TTX/Placebo)	Dosing	Schedule	Dosing Duration	Cumulative Dose
Conort			ттх	Placebo		
1	25	Placebo	NA	BID	4 days	NA
2	25	7.5 μg	BID	NA	4 days	60 µg
3	25	15 µg	BID	NA	4 days	120 µg
4	25	30 µg	QD	QD	4 days	120 µg
5	25	30 µg	BID	NA	4 days	240 µg

Study Procedures

Screening Phase Bhas Bhase Bhase Bhas Bhas Bhas Bhas Bhas Bhas Bhas Bhas	Baseline Period COMPLETION OF MEDICAL ASSESSMENT, PAIN CHARACTERIZATION • Stable pain (NPRS) • Inclusion-Exclusion	<section-header><section-header><section-header><section-header><section-header></section-header></section-header></section-header></section-header></section-header>	Follow-up Period EFFICACY AND SAFETY ASSESSMENT • Safety Labs (hematology, chemistry & urinalysis) • ECG • AE and ConMed Capture		
 Review of analgesic use Stable pain (NPRS) 		∇ ∇ ∇ ∇	 Vitals Pain reporting (NPRS) Questionnaires (SF-36, EORTC CIPN 20, GIC) 		
Screening Visit	Baseline Visit	Treatment Days	Weekly until Day 28		
-30 to -7	-7 to-1	1 2 3 4	7, 14, 21, 28		
	Days				

Study Populations

- 125 subjects randomized
- 125 in the ITT population
- 107 subjects in the PP population

Results

Primary	End	point –	Week 4	NPRS	Pain	Score
i i i i i i i ai y	LIIM				I am	JUIL

	Cohort 1 (7.5 μg BID)	Cohort 2 (15 µg BID)	Cohort 3 (30 µg QD)	Cohort 4 (30 μg BID)	Placebo
Week 1	-0.836	-0.891	-1.006	-1.244	-0.906
	(0.9553)	(0.8396)	(1.6116)	(1.5911)	(1.1193)
Week 2	-1.164	-1.218	-1.508	-1.433	-1.423
	(1.3583)	(1.1188)	(1.8307)	(1.7853)	(1.7218)
Week 3	-1.197	-1.277	-1.670	-1.555	-1.365
	(1.4770)	(1.6375)	(2.0198)	(1.5565)	(1.8792)
Week 4	-1.269	-1.052	-1.682	-1.529	-1.339
	(1.3959)	(1.5742)	(2.3231)	(1.8203)	(2.0681)

Change from baseline in the average scores at Week 4 is largest in Cohorts 3 and 4.

Responder Analyses: 30% reduction in average NPRS score from baseline to any week

	Cohort 1 (7.5 μg BID)	Cohort 2 (15 µg BID)	Cohort 3 (30 µg QD)	Cohort 4 (30 µg BID)	Placebo
Yes	9 (36.0%)	11 (45.8%)	10 (40.0%)	15 (57.7%)	8 (32.0%)
No	16 (64.0%)	13 (54.2%)	15 (60.0%)	11 (42.3%)	17 (68.0%)
P-value	0.333	0.0657	0.992	0.072	
		Cohort 1 (7.5 μg BID)	Cohort 2 (15 μg BID)	Cohort 3 (30 µg QD)	Cohort 4 (30 µg BID)
Odds Ratio (vs. placebo)		1.12	1.99	1.65	3.39
95% CI for Odds Ratio		(0.32, 3.96)	(0.56, 7.13)	(0.46, 5.90)	(0.96, 11.97)

Responder Analyses: 30% reduction in average NPRS score from baseline to any 10 consecutive days

	Cohort 1 (7.5 μg BID)	Cohort 2 (15 µg BID)	Cohort 3 (30 µg QD)	Cohort 4 (30 µg BID)	Placebo
Yes	8 (32.0%)	10 (41.7%)	10 (40.0%)	<mark>15 (57.7%)</mark>	8 (32.0%)
No	17 (68.0%)	14 (58.3%)	15 (60.0%)	<mark>11 (42.3%)</mark>	17 (68.0%)
P-value	0.178	0.871	0.935	0.027	
		Cohort 1 (7.5 μg BID)	Cohort 2 (15 µg BID)	Cohort 3 (30 µg QD)	Cohort 4 (30 μg BID)
Odds Ratio (vs. placebo)		0.90	1.68	1.63	3.90
95% CI for Odds Ratio		(0.25, 3.24)	(0.47, 6.06)	(0.45, 5.83)	(1.08, 14.09)


Treatment Emergent Adverse Events

Parameter	Cohort 1	Cohort 2	Cohort 3	Cohort 4	Placebo
Number of Subjects	21	22	20	24	18
with at least 1 AE	(84.0%)	(91.7%)	(80.0%)	(92.3%)	(72.0%)
	0	1	0	1	1
Number of SAE		(4.2%)	0	(3.8%)	(4.0%)

- Three patients suffered SAEs, two unrelated and one unlikely related to TTX
- Most AE reported were mild or moderate in severity
- Four subjects (all from Cohort 4) experienced a total of seven grade 3 AE (paresthesia, burning sensation, pain, hypertension, viral URI

C
Ne
dis
Pa
H
Pa
He
Di

*All grade 1 or 2 save for one event of grade 3 paresthesia.





• There were no grade 4 AE

System Organ Cohort1 Cohort4 Placebo lass Preferred Cohort2 Cohort3 (N=25) (N=24) (N=26) Term (N=25) (N=25) 20 ervous system 13 16 (52.0%) (66.7%) (68.0%) (76.9%) (44.0%) sorders aresthesia oral 11 (16.0%) (37.5%) (40.0%) (42.3%) (12.0%) ypesthesia oral 10 (20.0%) (38.5%) (12.0%) (29.2%) (24.0%) aresthesia 5 (20.0%) 7 (29.2%) 5 (20.0%) 7 (26.9%) 6 (24.0%) 3 (12.5%) **9 (34.6%)** 5 (20.0%) 1 (4.0%) eadache 6 (24.0%) **8 (30.8%)** 5 (20.0%) 4 (16.7%) 3 (12.0%) 3 (12.0%) izziness 2 (8.0%) 1 (3.8%) 2 (8.0%) Hypesthesia 2 (8.0%) 1 (4.2%)

Nervous system AE

Conclusions

- TTX was safe and well-tolerated in all cohorts
- 30 μg BID is the most promising dose / schedule • Phase III trial of TTX for CINP is in development

Disclosure

This study was funded by WEX Pharmaceuticals Inc.